Oramed Pharmaceuticals Inc. ORMP · NASDAQ
$4.23 +1.68% (+$0.07)
Summary
54 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $15.2M against $733.0K.
- The share price is below the Bulios Fair Price.
What to watch
- Revenue fell by 9.6% a year over the last 3 years.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 1.0 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 5.9% a year over 5 years. Over the last 3 years it fell by 9.6% a year.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
High, safe- Yield
- 5.91%
- Paid out of profit
- 5.9%
The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 6
- Hold 2
- Sell 0
No analyst has published a price target.
75% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.